poly(A) binding protein interacting protein 2Genealiases: PAIP-2 · PAIP2A
Q-omics provides the consensus-scored PAIP2 profile across patient tissues and cancer cell-line models. PAIP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PAIP2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, PAIP2 protein abundance shows 24,933 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, THCA, and HNSC as cancer lineages where PAIP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAIP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAIP2 survival associations across molecular data types. PAIP2 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAIP2 RNA expression–survival associations across cancer types. High PAIP2 expression shows unfavorable associations in HNSC, UVM, KICH, STAD and CESC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PAIP2 RNA expression.
This table summarizes PAIP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PAIP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAIP2 shows lower tumor expression in THCA, KICH and LUAD and higher tumor expression in KIRC, LIHC and BRCA. The THCA box plot shows higher PAIP2 RNA expression in normal versus tumor tissue (log2 FC = −0.874, t-test p < 0.001).
This table shows molecular features associated with PAIP2 in patient tissues and cancer cell lines. In patient samples, PAIP2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, PAIP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Myeloma.
